Recent study has shown that among the most serious forms of cancer affecting the worlds’ population is prostate cancer. In the USA this figure is more pronounced in the African male adults. The ideal age at which the disease becomes apparent is 40 years. The best way to handle this cancer is by early detection through screening. This has been provided by Cancer Treatment Centers of America (CTCA) in conjunction with other state holders.
CTCA is based in Florida, from where it operates five branches. These hospitals are found in Atlanta, Chicago, Phoenix, Tulsa and Philadelphia. They operate with a high degree of efficiency providing a holistic care to cancer patient. These centers have collaborated with other organizations such as NFL to educate the members of public on important of being tested for cancerous cells in the body.
The hospital uses a team approach to reach a conclusive diagnosis. Modern equipment is deployed to achieve credible results. Once taken up by the system, a variety of treatment options are available to suit the ailing person. This is in terms of availability to attend clinic, reaction of the body to the form of treatment, among others.
Treatment options include immunotherapy that deals in enhancing the body’s ability to combat the cancer. Secondly, chemotherapy that uses drugs to suppress disease. There is also radiotherapy that is based on using electromagnetic waves of controlled frequency. The three approaches are effective in dealing with this kind of cancer in most cases.
CTCA has been a pioneer in giving the American citizen a friendly approach to fight cancer. The package also includes counseling sessions that are crucial to an individual in the healing process. This emotional support compliments the physical well-being. The staff in the centers is composed of experts, top in their fields, ready to assist.
Seattle Genetics and its co-founder, Clay Siegall, are paving the way to make cancer a thing of the past.
Founded in 1998, Seattle Genetics is a research and drug development company focusing on scientific innovation with a passion for patients. They have developed a pipeline of antibody-based cancer therapies and have the first ever FDA approved antibody-drug conjugate (ADC), ADCETRIS. They are leaders in the world for ADC’s. The drug is designed for patients with Hodgkin lymphoma and works by empowering antibodies “designed to harness the targeting ability of monoclonal antibodies by linking them to cell-killing agents.” Dr. Siegall is proud of the fact that there are more than 15,000 people who have been treated with ADCETRIS. The drug is approved and used in over 50 countries.
He sees the future of drug development target on specific tumor antigens using ADC’s to eliminate cancers altogether. There are three ADC’s currently finishing clinical research to help with these measures. His goal is to “redefine the way frontline HL and mature T-cell lymphoma patients are treated by adding ADCETRIS into the standard regimens while dropping the most toxic agents.” The outlook for the other ADC’s is encouraging as well. Reports on these studies will be out soon with further study results coming next year. Research that the company is doing with ADC’s hopes to work with other forms of cancer such as leukemia, colon, breast, and many other forms of cancer.
Besides Seattle Genetics, Dr. Siegall provides on the board of other biotechnology companies, including Ultragenyx, Mirna Therapeutics, and Adler Biopharmaceuticals. His work with these companies will help to further better treatments for cancer and other high-risk medical needs.
Dr. Siegall received his undergraduate degree in Zoology from the University of Maryland and his Ph.D. in Genetics from The George Washington University. He has formerly worked with Bristol-Myers Squibb and the National Cancer Institute. He has been published over 70 times and holds 15 patents.